Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University: Head and Neck Neoplasms trials

The registry lists 11 Head and Neck Neoplasms studies with Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 9Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCCRecruitingNCT07882888Phase 2
• Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT07662746Phase 2
• Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesRecruitingNCT07662681Phase 1/2
• Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT07632339Phase 2
• Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell CarcinomaRecruitingNCT07445048Phase 3
• Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCCRecruitingNCT06876844Phase 2
• High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)Status unknownNCT04126460Phase 2
• Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland TumorsCompletedNCT02921984Phase 1
• Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland CarcinomasCompletedNCT02776163Phase 2
• Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and NeckCompletedNCT02776137Phase 2
• Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown PrimaryStatus unknownNCT02764216Phase 2